(NASDAQ: ESPR) Esperion Therapeutics's forecast annual revenue growth rate of 16.02% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.27%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.38%.
Esperion Therapeutics's revenue in 2025 is $259,574,000.On average, 4 Wall Street analysts forecast ESPR's revenue for 2025 to be $70,440,485,194, with the lowest ESPR revenue forecast at $57,610,637,620, and the highest ESPR revenue forecast at $82,847,375,116. On average, 4 Wall Street analysts forecast ESPR's revenue for 2026 to be $68,899,087,978, with the lowest ESPR revenue forecast at $60,819,486,909, and the highest ESPR revenue forecast at $81,896,017,698.
In 2027, ESPR is forecast to generate $83,805,867,714 in revenue, with the lowest revenue forecast at $80,090,420,600 and the highest revenue forecast at $90,378,954,672.